School of Medicine

Paul J. Shaw at the School of Medicine received a one-year $2.3 million grant from the National Institute on Aging of the National Institutes of Health (NIH) to research interactions between sleep and Alzheimer’s disease.

Gregory R. Bowman at the School of Medicine received a one-year $1.8 million grant from the National Institute on Aging of the National Institutes of Health (NIH) for Alzheimer’s disease research.

Xuntian Jiang at the School of Medicine received a five-year $2 million grant from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH).

Researchers at Washington University School of Medicine are joining scientists around the country to conduct a study aimed at understanding how prenatal factors and early life experiences influence brain development and behavior in young children.

Researchers at Washington University School of Medicine have found that multidrug-resistant bacteria and bacterial spores can be killed by ultrashort-pulse lasers. The findings could lead to new ways to sterilize wounds and blood products without damaging human cells.

Stacey Lynn Rentschler at the School of Medicine received a four-year $2 million grant from the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH).

Brian Kim, MD, at the School of Medicine, received a five-year, $2.4 million grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (NIH) to research skin inflammation.

Urologic oncologist Sam Bhayani, MD, has been named to lead the Division of Urologic Surgery in the Department of Surgery at Washington University School of Medicine.

Researchers at Washington University are receiving one of 19 grant awards that will support data science research and training activities in Africa. The researchers will focus on developing new training programs in health data science in Rwanda.

People taking TNF inhibitors, a kind of immunosuppressive drug used to treat rheumatoid arthritis and other autoimmune conditions, produced a weaker and shorter-lived antibody response after two doses of Pfizer’s COVID-19 vaccine, according to a study from Washington University School of Medicine.